MedInCell Stock Drops 3% but Still Up +74% Over the Year
The Montpellier-based biotech's stock fell by 2.78% to €26.62 at mid-session, in a Paris market weighed down by soaring long-term rates and a surge in Brent crude. Nevertheless, MedInCell's stock remains up nearly 74% over the year and has gained more than 8% over three months.
A Decline in a Difficult Session for Rate-Sensitive Stocks
The SBF 120 is down 0.69% at 6,012.97 points and the CAC 40 has lost 0.65% at 7,900.79 points during the session. Pressure comes from the bond markets: the yield on the 10-year U.S. Treasury has risen to 4.63%, a high since February 2025, while the 30-year Japanese bond hit a record around 4.20%. Brent crude is trading above $111 per barrel, fueling the scenario of sustained inflation and higher interest rates for longer. In this unfavorable environment for growth stocks and biotechs, MedInCell ranks low in the SBF 120, behind Ipsen, Nanobiotix, and Nexity. However, the decline remains moderate considering the recent trajectory: the target raised to €52 by Oddo on Friday pushed the stock to €28.14 at the end of the week, a level that was a high point for several months.
The Stock Maintains a Comfortable Technical Cushion Over Its Moving Averages
Despite today's decline, MedInCell is trading above its three key moving averages. The price at €26.62 is 4.84% above the MM20 (€25.39) and 13.42% above the MM50 (€23.47), indicating that the medium-term momentum remains bullish. The RSI at 62 has exited the buying zone without entering oversold territory. The technical support identified at €21.68 leaves room before the trend is questioned. In the shorter term, the resistance at €28.72, corresponding to the peak on May 15, has not been breached. The biotech had crossed a graphical threshold before its R&D day on May 11, which supported the rally in the first half of the month. The next key date on the calendar is the general assembly in 2026, scheduled for September 10.
